Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The law about advance directives is evolving but, in France, few people write it.
Te main endpoint of this research is to estimate the proportion of patients who have written their advance directives or considering doing so in onco-dermatologic population. If this rate remains low, some insights on the reasons will be able to be advanced looking at the point of view and opinion of patients about this topic.
Seconds endpoints are :
For patients against or not planning to write it, understand their reasons
Estimate the proportion of patients requesting information and understand how they would like to receive it.
Investigate a possible association between the stage of the oncological disease and the positioning of the patient concerning advance directives.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| patients accepting to answer to the survey | patients with a skin lymphoma OR melanoma OR advanced skin squamous cell carcinoma OR advanced basal cell carcinoma accepting to answer to the anonymous survey |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| no intervention, only complete a survey | Other | we will ask patients to answer to a survey |
|
| Measure | Description | Time Frame |
|---|---|---|
| Writing by the patient of its advance directives | Writing by the patient of his advance directves and, if not writing, positioning of the patient (rather favorable or rather unfavorable) as to the writing of his advance directives. | when the patient complete the survey |
| Measure | Description | Time Frame |
|---|---|---|
| reason for not writing advance directives | In patients who have not written their advance directives: reason for not writing the advance directives. | when the patient complete the survey |
| Patient wishing to be more informed about the adavance directives during its management and, if so, by what means. |
Not provided
Inclusion Criteria:
> 18 ya
With one of the diagnoses below:
Exclusion Criteria:
Patients not in possession of all of its cognitive abilities Patients who can't read patients who don't speak french
Not provided
Not provided
Not provided
Cf beyond
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Anne-Claire BURSZTEJN | Contact | 0383157146 | ac-bursztejn@chru-nancy.fr |
| Name | Affiliation | Role |
|---|---|---|
| anne-claire bursztejn | CHRU Nancy | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CHRU Nancy-Brabois hospital | Recruiting | Vandœuvre-lès-Nancy | 54500 | France |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| when the patient complete the survey |
| ID | Term |
|---|---|
| D009369 | Neoplasms |
| D012878 | Skin Neoplasms |
| D008545 | Melanoma |
| D016410 | Lymphoma, T-Cell, Cutaneous |
| D002280 | Carcinoma, Basal Cell |
| ID | Term |
|---|---|
| D009371 | Neoplasms by Site |
| D012871 | Skin Diseases |
| D017437 | Skin and Connective Tissue Diseases |
| D018358 | Neuroendocrine Tumors |
| D017599 | Neuroectodermal Tumors |
| D009373 | Neoplasms, Germ Cell and Embryonal |
| D009370 | Neoplasms by Histologic Type |
| D009380 | Neoplasms, Nerve Tissue |
| D018326 | Nevi and Melanomas |
| D016399 | Lymphoma, T-Cell |
| D008228 | Lymphoma, Non-Hodgkin |
| D008223 | Lymphoma |
| D008232 | Lymphoproliferative Disorders |
| D008206 | Lymphatic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D007160 | Immunoproliferative Disorders |
| D007154 | Immune System Diseases |
| D002277 | Carcinoma |
| D009375 | Neoplasms, Glandular and Epithelial |
| D018295 | Neoplasms, Basal Cell |
Not provided
Not provided